Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031512 · ClinicalTrials.gov registry record · Phase 2
Pleconaril Enteroviral Sepsis Syndrome
A Phase 2 study of Enterovirus Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
- 20
- Study locations
NCT00031512: Completed Phase 2 study of Enterovirus Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00031512 is a Phase 2 study of Enterovirus Infection that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 61 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 18 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00031512, a Phase 2 study of Enterovirus Infection, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
- 20
- Study locations
Study Summary
A common group of viruses that infect humans are enteroviruses. Enteroviruses produce illnesses in children which may range from very mild (summer colds) to severe (infections of the brain, liver, and heart). The purpose of this study is to determine if a new drug called pleconaril helps treat babies with enteroviral sepsis. In addition, researchers are attempting to determine a safe and effective dose of pleconaril to help babies with this disease. Infants who are 15 days or younger when diagnosed with enteroviral disease are eligible for this study. Two out of 3 babies will be randomly assigned to receive Pleconaril and the other one out of three will receive a placebo (inactive substitute). Participants will be hospitalized while receiving study medication. Babies will receive standard treatment care for their symptoms and will be observed for their medical progress. Participants may be in the study for up to 2 years.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Pleconaril
Study Locations (20)
California
- Ronald Reagan University of California Los Angeles Medical Center - Los Angeles
- Rady Children's Hospital San Diego - San Diego
- Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases - Stanford
Alabama
- Children's of Alabama Child Health Research Unit (CHRU) - Birmingham
Arkansas
- University of Arkansas - Arkansas Children's Hospital Research Institute - Little Rock
Colorado
- Children's Hospital Colorado - Infectious Disease - Aurora
Florida
- University of Florida - Shands Children's Hospital - Gainesville
Illinois
- The University of Chicago - Comer Children's Hospital - Infectious Diseases - Chicago
Kentucky
- University of Louisville School of Medicine - Norton Children's Hospital - Infectious Diseases - Louisville
Louisiana
- Tulane University - Tulane Medical Center - Pediatrics - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2001-06-27 |
| Est. Completion | 2012-09-15 |
| Phase | Phase 2 |
What the finished NCT00031512 record still lists
NCT00031512 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (54% lower).
The record links to 1 condition, with Enterovirus Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00031512 names 20 study sites across 18 states, led by California, Alabama, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00031512 about?
NCT00031512 is a clinical study titled "Pleconaril Enteroviral Sepsis Syndrome". A common group of viruses that infect humans are enteroviruses. Enteroviruses produce illnesses in children which may range from very mild (summer colds) to severe (infections of the brain, liver, and heart). The purpose of this study is to determine if a new drug called pleconaril helps treat babie...
What is the current status of trial NCT00031512?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2001-06-27. Estimated completion is 2012-09-15.
What conditions does trial NCT00031512 study?
This clinical trial studies the following conditions: Enterovirus Infection.
What interventions are being tested in trial NCT00031512?
The interventions under investigation include: Placebo (OTHER), Pleconaril (DRUG).
Who is sponsoring clinical trial NCT00031512?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00031512 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Enterovirus Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00031512's enrollment target sits among peer trials
61 1026th of 2000 higher than 974 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI